Ascendis Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Ascendis Pharma AS
ASND Stock  USD 223.41  7.09  3.28%   
Ascendis Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ascendis Pharma's valuation are provided below:
Gross Profit
625.2 M
Profit Margin
(0.32)
Market Capitalization
13.3 B
Enterprise Value Revenue
15.8918
Revenue
720.1 M
There are over one hundred nineteen available fundamental signals for Ascendis Pharma AS, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Ascendis Pharma's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 11.5 B. The current year's Enterprise Value is expected to grow to about 11.8 B

Ascendis Pharma Total Revenue

726.3 Million

Check Ascendis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascendis Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.8 M, Interest Expense of 81.3 M or Selling General Administrative of 470.4 M, as well as many indicators such as Price To Sales Ratio of 15.11, Dividend Yield of 0.0 or Days Sales Outstanding of 48.19. Ascendis financial statements analysis is a perfect complement when working with Ascendis Pharma Valuation or Volatility modules.
  
Build AI portfolio with Ascendis Stock
Check out the analysis of Ascendis Pharma Correlation against competitors.

Ascendis Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.4 B1.3 B559.6 M
Slightly volatile
Total Current Liabilities1.1 B1.1 B290.8 M
Slightly volatile
Property Plant And Equipment Net153.7 M146.4 M55.1 M
Slightly volatile
Current Deferred Revenue5.4 M4.9 M7.1 M
Slightly volatile
Accounts Payable95.1 M90.6 M38.9 M
Slightly volatile
Cash331 M615.8 M285.9 M
Slightly volatile
Non Current Assets Total203.2 M193.5 M85.8 M
Slightly volatile
Non Currrent Assets Other2.8 M2.7 M1.1 M
Slightly volatile
Cash And Short Term Investments380 M615.8 M328.1 M
Slightly volatile
Net Receivables165.5 M157.6 M32.6 M
Slightly volatile
Good Will2.8 M3.5 M3.5 M
Slightly volatile
Common Stock Total Equity4.2 M8.3 M4.8 M
Slightly volatile
Liabilities And Stockholders Equity1.4 B1.3 B559.6 M
Slightly volatile
Non Current Liabilities Total415.6 M395.8 M110.9 M
Slightly volatile
Other Current Assets21.4 M33.7 M18.4 M
Slightly volatile
Total Liabilities1.5 B1.5 B394 M
Slightly volatile
Property Plant And Equipment Gross234 M222.9 M78.3 M
Slightly volatile
Total Current Assets1.2 B1.1 B473.8 M
Slightly volatile
Common Stock5.7 M8.3 M5 M
Slightly volatile
Other Current Liabilities511.4 M487.1 M106.8 M
Slightly volatile
Common Stock Shares Outstanding42.9 M60.6 M35.9 M
Slightly volatile
Other Stockholder Equity2.7 B2.5 B1.1 B
Slightly volatile
Net Tangible Assets374.1 M297.3 M270.4 M
Slightly volatile
Other Assets2.3 M2.2 M1 M
Slightly volatile
Property Plant Equipment155.9 M148.5 M58.4 M
Slightly volatile
Intangible Assets204.2 K214.9 K17.8 B
Pretty Stable
Net Invested Capital662.2 M709 M434.8 M
Slightly volatile
Net Working Capital37.6 M39.6 M302.6 M
Pretty Stable
Capital Stock8.1 M8.3 M6.6 M
Slightly volatile

Ascendis Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization17.8 M17 M7.4 M
Slightly volatile
Interest Expense81.3 M77.5 M18 M
Slightly volatile
Selling General Administrative470.4 M448 M120 M
Slightly volatile
Total Revenue726.3 M691.7 M131.4 M
Slightly volatile
Gross Profit618 M588.5 M112.8 M
Slightly volatile
Other Operating Expenses863.7 M822.6 M305.3 M
Slightly volatile
Research Development198.2 M283.5 M161.4 M
Slightly volatile
Total Operating Expenses755.4 M719.4 M286.7 M
Slightly volatile
Interest Income8 M15.3 M7.6 M
Slightly volatile
Reconciled Depreciation12.9 M17.7 M7.3 M
Slightly volatile
Selling And Marketing Expenses4.5 M5.1 M5.5 M
Slightly volatile

Ascendis Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation122 M116.2 M39 M
Slightly volatile
Begin Period Cash Flow301.1 M493.1 M245 M
Slightly volatile
Depreciation17.8 M17 M7.4 M
Slightly volatile
Capital Expenditures6.7 M8.2 M5.4 M
Slightly volatile
End Period Cash Flow353.5 M615.8 M287.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio15.1115.9019213
Pretty Stable
Days Sales Outstanding48.1983.177268.2037
Pretty Stable
Stock Based Compensation To Revenue0.220.241.8482
Pretty Stable
Capex To Depreciation0.460.47951.1492
Slightly volatile
EV To Sales15.4616.2715192
Pretty Stable
Inventory Turnover0.360.34230.1011
Slightly volatile
Days Of Inventory On Hand1 K1.1 K6.1 K
Slightly volatile
Payables Turnover1.21.13860.2411
Slightly volatile
Sales General And Administrative To Revenue0.670.72.0778
Pretty Stable
Research And Ddevelopement To Revenue0.390.409911.9059
Very volatile
Capex To Revenue0.01120.01180.4825
Pretty Stable
Cash Per Share6.2910.16027.0031
Slightly volatile
Days Payables Outstanding3053214.7 K
Slightly volatile
Intangibles To Total Assets0.00270.00280.0436
Slightly volatile
Current Ratio0.991.0375.2148
Very volatile
Receivables Turnover4.174.3882111
Very volatile
Capex Per Share0.10.13450.1128
Slightly volatile
Average Receivables129.6 M145.8 M159.1 M
Slightly volatile
Revenue Per Share11.9811.4132.5738
Slightly volatile
Interest Debt Per Share16.4415.65624.7185
Slightly volatile
Debt To Assets0.70.66930.2513
Slightly volatile
Graham Number1.142.01.8642
Slightly volatile
Operating Cycle1 K1.1 K1.1 K
Slightly volatile
Days Of Payables Outstanding3053214.7 K
Slightly volatile
Ebt Per Ebit0.821.56050.9926
Slightly volatile
Long Term Debt To Capitalization1.021.7320.5005
Slightly volatile
Total Debt To Capitalization1.291.22970.452
Slightly volatile
Quick Ratio0.720.75515.0916
Very volatile
Net Income Per E B T0.791.07230.9757
Pretty Stable
Cash Ratio0.550.57614.5266
Very volatile
Cash Conversion Cycle870829462
Slightly volatile
Days Of Inventory Outstanding1 K1.1 K6.1 K
Slightly volatile
Days Of Sales Outstanding48.1983.177268.2037
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.130.84261.0832
Slightly volatile
Fixed Asset Turnover4.024.72434.7902
Slightly volatile
Debt Ratio0.70.66930.2513
Slightly volatile
Price Sales Ratio15.1115.9019213
Pretty Stable
Asset Turnover0.560.53130.2807
Pretty Stable
Gross Profit Margin0.620.85080.6182
Slightly volatile

Ascendis Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap11.5 B11 B4 B
Slightly volatile
Enterprise Value11.8 B11.3 B3.9 B
Slightly volatile

Ascendis Fundamental Market Drivers

Forward Price Earnings45.4545
Cash And Short Term Investments615.8 M

Ascendis Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ascendis Pharma Financial Statements

Ascendis Pharma stakeholders use historical fundamental indicators, such as Ascendis Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ascendis Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascendis Pharma's assets and liabilities are reflected in the revenues and expenses on Ascendis Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascendis Pharma AS. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.9 M5.4 M
Total Revenue691.7 M726.3 M
Cost Of Revenue103.2 M98 M
Stock Based Compensation To Revenue 0.24  0.22 
Sales General And Administrative To Revenue 0.70  0.67 
Research And Ddevelopement To Revenue 0.41  0.39 
Capex To Revenue 0.01  0.01 
Revenue Per Share 11.41  11.98 
Ebit Per Revenue(0.19)(0.20)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:
How To Invest In Ascendis
Details
Is Ascendis Stock a good investment?
Details
What is Ascendis Pharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ascendis Pharma Correlation against competitors.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Will Biotechnology sector continue expanding? Could Ascendis diversify its offerings? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ascendis Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.46)
Revenue Per Share
11.882
Quarterly Revenue Growth
0.423
Return On Assets
(0.07)
Return On Equity
(8.18)
Understanding Ascendis Pharma AS requires distinguishing between market price and book value, where the latter reflects Ascendis's accounting equity. The concept of intrinsic value - what Ascendis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ascendis Pharma's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Ascendis Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascendis Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ascendis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY